Turkish lupusPRO: Cross-cultural validation study for lupus

Clinical Rheumatology

Volumn 33, Issue 8, 2014, Pages 1079-1084

  Kaya, Arif ^a   Goker, Berna ^a   Cura, Elife Senem ^a   Tezcan, Mehmet Engin ^a   Tufan, Abdurrahman ^a   Mercan, Ridvan ^a   Bitik, Berivan ^a   Haznedaroglu, Seminur ^a   Ozturk, Mehmet Akif ^a   Mikolaitis Preuss, Rachel A ^b   Block, Joel A ^b   Jolly, Meenakshi ^b  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Patient reported outcomes; Quality of life; Systemic lupus erythematosus; Turkish

Indexed keywords

ADULT; CULTURAL ANTHROPOLOGY; CULTURAL FACTOR; FACTORIAL ANALYSIS; FEMALE; HEALTH STATUS; HUMAN; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PUBLICATION; QUALITY OF LIFE; QUESTIONNAIRE; REPRODUCIBILITY; SELF REPORT; SEVERITY OF ILLNESS INDEX; TURKEY; VALIDATION STUDY; YOUNG ADULT;

ADULT; CROSS-CULTURAL COMPARISON; CULTURE; FACTOR ANALYSIS, STATISTICAL; FEMALE; HEALTH STATUS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SELF REPORT; SEVERITY OF ILLNESS INDEX; TRANSLATIONS; TURKEY; YOUNG ADULT;

EID: 84904443597     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-013-2345-9     Document Type: Article

References (24)

1. Alarcón GS, McGwin G Jr, Brooks K et al (2002) Systemic lupus erythematosus in three ethnic groups. XI. Sources of discrepancy in perception of disease activity: a comparison of physician and patient visual analog scale scoresb. Arthritis Rheum 47(4):408-413 (Pubitemid 34856130)
2. JollyM, Utset TO (2004) Can disease specific measures for systemic lupus erythematosus predict patients health related quality of life? Lupus 13(12):924-926 (Pubitemid 39664951)
3. FDA Guidance on Patient Reported Outcomes. [http://www.fda.gov/cder/ guidance/index htm 2006]. Accessed 29 Jul 2013
4. Jolly M, Pickard AS, Block JA et al (2012) Disease-specific patient reported outcome tools for systemic lupus erythematosus. Semin Arthritis Rheum 42(1):56-65
5. Jolly M, Block JA, Mikolaitis RA et al (2011) Spanish LupusPRO: Cross Cultural Validation Study for Lupus. Arthritis Rheum 63 (10s):S725
6. Guillemin F, Bombardier C, Beaton D (1993) Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol 46(12):1417-1432 (Pubitemid 24017263)
7. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725
8. Ware JE (1996) The SF-36 Health Survey. In: Spiker B (ed) Quality of life and pharmacoeconomics in clinical trials, 2nd edn. Lippincott-Raven, Philadelphia, pp 337-345
9. Petri M, Kim MY, Kalunian KC et al (2005) Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 353(24):2550-2558 (Pubitemid 41785892)
10. Ruperto N, Hanrahan LM, Alarcon GS et al (2011) International consensus for a definition of disease flare in lupus. Lupus 20(5):453-462
11. Gladman D, Ginzler E, Goldsmith C et al (1996) The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39(3):363-369 (Pubitemid 26085211)
12. Brazier J, Roberts J, Deverill M (2002) The estimation of a preference-based measure of health from the SF-36. J Health Econ 21(2):271-292 (Pubitemid 34143147)
13. Hays RD, Anderson R, Revicki D (1993) Psychometric considerations in evaluating health-related quality of life measures. Qual Life Res 2:441-449 (Pubitemid 24035216)
14. Mplus User 's Guide [computer program]. Version 1. Los Angeles: Muthén & Muthén; 1998.
15. Hu L, Bentler PM (1999) Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Structural equation Modeling 6:1-55
16. McElhone K, Abbott J, Teh SL (2006) A review of health related quality of life in systemic lupus erythematosus. Lupus 15:633-643 (Pubitemid 44682824)
17. Furie R, Petri M, Zamani O et al (2011) A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63(12):3918-3930
18. Fries JF, Spitz P, Kraines RG, Holman HR (1980) Measurement of patient outcome in arthritis. Arthritis Rheum 23(2):137-145 (Pubitemid 10164318)
19. Strand V, Chu AD (2011) Measuring outcomes in systemic lupus erythematosus clinical trials. Expert Rev Pharmacoecon Outcomes Res 11(4):455-468
20. Kuriya B, Gladman DD, Ibanez D, Urowitz MB (2008) Quality of Life over time in patients with systemic lupus erythematosus. Arthritis Rheum 59(2):181-185 (Pubitemid 351272952)
21. Leong KP, Kong KO, Thong BY et al (2005) Development and preliminary validation of a systemic lupus erythematosus-specific quality-of-life instrument (SLEQOL). Rheumatology 44(10):1267-1276 (Pubitemid 41487960)
22. McElhone K, Abbott J, Shelmerdine J et al (2007) Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. Arthritis Rheum 57(6):972-979 (Pubitemid 47237322)
23. Doward LC, McKenna SP,Whalley D et al (2009) The development of the L-QoL: a quality-of-life instrument specific to systemic lupus erythematosus. Ann Rheum Dis 68(2):196-200
24. Jolly M, Cornejo J, Mikolaitis RA, Block JA (2011) LupusPRO and responsiveness the changes in health status and disease activity over time. Arthritis Rheum 63(10s):S898